Evidence map›Paper›PMID 41254116›Full record

ArticleLeukemia2026

Putative multiple myeloma susceptibility genes identified by exome sequencing of 347 familial and early-onset cases.

Maroulio Pertesi, Delphine Demangel, Abhishek Niroula, Emeline Perrial, Maria Laura Mahecha Escobar, Maxime Vallée, Christine Liacos, Mehmet K Samur, Adam S Sperling, Nikhil C Munshi and 8 more

Abstract readLetter
PubMed Publisher
In one paragraph

Article in Leukemia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Maroulio PertesiDepartment of Laboratory Medicine, Division of Hematology, Lund University, Lund, Sweden. maroulio.pertesi@med.lu.se.ORCID http://orcid.org/0000-0002-4869-8925
Delphine DemangelHospices Civils de Lyon, Lyon, France.
Abhishek NiroulaDepartment of Medical Biochemistry and Cell Biology, Institute of Biomedicine, University of Gothenburg, Gothenburg, Sweden.
Emeline PerrialHospices Civils de Lyon, Lyon, France.
Maria Laura Mahecha EscobarDepartment of Laboratory Medicine, Division of Hematology, Lund University, Lund, Sweden.ORCID http://orcid.org/0009-0002-7872-9865
Maxime ValléeGenetic Cancer Susceptibility, International Agency for Research on Cancer, Lyon, France.ORCID http://orcid.org/0000-0002-3616-9508
Christine LiacosDepartment of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
Mehmet K SamurDana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0002-9978-5682
Adam S SperlingDana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0002-9369-4413
Nikhil C MunshiDana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0002-7344-9795
Efstathios KastritisDepartment of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
Meletios A DimopoulosDepartment of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.ORCID http://orcid.org/0000-0001-8990-3254
James D McKayGenetic Cancer Susceptibility, International Agency for Research on Cancer, Lyon, France.
Ulf-Henrik MellqvistSouthern Älvsborg Hospital, Borås, Sweden.
Markus HanssonDepartment of Laboratory Medicine, Division of Hematology, Lund University, Lund, Sweden.ORCID http://orcid.org/0000-0002-7715-4548
Charles DumontetHospices Civils de Lyon, Lyon, France.
Intergroupe Francophone du Myélome (IFM)
Björn NilssonDepartment of Laboratory Medicine, Division of Hematology, Lund University, Lund, Sweden. bjorn.nilsson@med.lu.se.ORCID http://orcid.org/0000-0001-5542-0254

Funding

Cancerfonden (Swedish Cancer Society) 200696Gunnar Nilssons Cancerstiftelse (Gunnar Nilsson Cancer Foundation) GN-2020-26-183, GN-2021-31-261Institut National Du Cancer (French National Cancer Institute) 2021-025U.S. Department of Health & Human Services | National Institutes of Health (NIH) P01-155258, P50-CA100707U.S. Department of Health & Human Services | National Institutes of Health (NIH) P01-155258, P50-CA100707, K08CA252174Vetenskapsrådet (Swedish Research Council) 2017-02023, 2018-00424World Health Organization 001
6 · The paper itself

Abstract

Multiple myeloma (MM) is the second most common blood malignancy, with several lines of evidence supporting an inherited genetic component. Here, we sequenced 177 affected individuals from 128 families, and 170 early-onset MM cases diagnosed before 55 years of age. Samples were identified and collected through nationwide efforts in France, Sweden, and Greece. We focused on rare germline protein truncating and likely deleterious missense variants in genes harboring variants in at least two families showing variant-disease segregation, and in additional index (≥2) and/or early-onset (≥2) cases. We identified likely pathogenic variants in ATM (N = 12), ANGPTL6 (N = 5), and FBXW9 (N = 6). Additionally, we detected variants in previously reported MM predisposition genes, including DIS3, EP300, and KDM1A. Our results represent the largest sequencing study on familial and early-onset MM to date, and further illuminate the constitutional genetic basis of MM.

Indexed as

ExomeExome SequencingGenetic Predisposition to DiseaseMultiple MyelomaAdultAge of OnsetFemaleHumansMaleMiddle AgedPedigree

Identifiers

PMID41254116

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.